N-[2-[3-(difluoromethylsulfonylamino)phenyl]propan-2-yl]-5-(6-ethoxypyrazin-2-yl)-1,3-thiazole-2-carboxamide
C20H21F2N5O4S2 — CID 163271370
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[2-[3-(difluoromethylsulfonylamino)phenyl]propan-2-yl]-5-(6-ethoxypyrazin-2-yl)-1,3-thiazole-2-carboxamide
N-[2-[3-(difluoromethylsulfonylamino)phenyl]propan-2-yl]-5-(6-ethoxypyrazin-2-yl)-1,3-thiazole-2-carboxamide (PubChem CID 163271370) has the molecular formula C20H21F2N5O4S2 and a molecular weight of 497.55 g/mol. Its IUPAC name is N-[2-[3-(difluoromethylsulfonylamino)phenyl]propan-2-yl]-5-(6-ethoxypyrazin-2-yl)-1,3-thiazole-2-carboxamide.
Molecular Properties
| Compound Name | N-[2-[3-(difluoromethylsulfonylamino)phenyl]propan-2-yl]-5-(6-ethoxypyrazin-2-yl)-1,3-thiazole-2-carboxamide |
|---|---|
| PubChem CID | 163271370 |
| Molecular Formula | C20H21F2N5O4S2 |
| Molecular Weight | 497.55 g/mol |
| Exact Mass | 497.10 |
| IUPAC Name | N-[2-[3-(difluoromethylsulfonylamino)phenyl]propan-2-yl]-5-(6-ethoxypyrazin-2-yl)-1,3-thiazole-2-carboxamide |
| SMILES | CCOc1cncc(-c2cnc(C(=O)NC(C)(C)c3cccc(NS(=O)(=O)C(F)F)c3)s2)n1 |
| InChI | InChI=1S/C20H21F2N5O4S2/c1-4-31-16-11-23-9-14(25-16)15-10-24-18(32-15)17(28)26-20(2,3)12-6-5-7-13(8-12)27-33(29,30)19(21)22/h5-11,19,27H,4H2,1-3H3,(H,26,28) |
| InChIKey | CXSXCPWNBMNRBQ-UHFFFAOYSA-N |
| XLogP | 3.63 |
| TPSA | 123.17 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 497.55 |
| LogP ≤ 5 | 3.63 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 163271370 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.